Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K Park; J Vansteenkiste; K H Lee; G Pentheroudakis; C Zhou; K Prabhash; T Seto; P J Voon; D S W Tan; J C H Yang; J Wang; K Govind Babu; Y Nakayama; A Alip; K L M Chua; J C-H Cheng; S Senan; Y C Ahn; T-Y Kim; H K Ahn; S Peters; T Yoshino; J-Y Douillard

doi:10.1016/j.annonc.2019.10.026

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.

Authors

K Park¹, J Vansteenkiste², K H Lee³, G Pentheroudakis⁴, C Zhou⁵, K Prabhash⁶, T Seto⁷, P J Voon⁸, D S W Tan⁹, J C H Yang¹⁰, J Wang¹¹, K Govind Babu¹², Y Nakayama¹³, A Alip¹⁴, K L M Chua¹⁵, J C-H Cheng¹⁶, S Senan¹⁷, Y C Ahn¹⁸, T-Y Kim¹⁹, H K Ahn²⁰, S Peters²¹, T Yoshino²², J-Y Douillard²³

Affiliations

¹ Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: kpark@skku.edu.
² Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium.
³ Department of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
⁴ Department of Medical Oncology, University of Ioannina, Ioannina, Greece.
⁵ Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China.
⁶ Medical Oncology, Tata Memorial Hospital, Mumbai, India.
⁷ Thoracic Oncology/Clinical Oncology & Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
⁸ Radiotherapy and Oncology Department, Hospital Umum Sarawak, Kuching, Malaysia.
⁹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
¹⁰ Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
¹¹ Medical Oncology Department, Cancer Hospital Chinese Academy of Medical Science, China National Cancer Center, Beijing, China.
¹² Department of Medical Oncology, Kidwai Memorial Institute of Oncology and HCG Hospitals, Bangalore, India.
¹³ Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
¹⁴ Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
¹⁵ Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
¹⁶ Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
¹⁷ Department of Radiation Oncology, Amsterdam University Medical Center, VUmc location, Amsterdam, The Netherlands.
¹⁸ Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
¹⁹ Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
²⁰ Division of Medical Oncology, Gachon University Gil Medical Center, Incheon, Korea.
²¹ Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland.
²² Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
²³ Chief Medical Officer, ESMO, Lugano, Switzerland.

PMID: 31959336
DOI: 10.1016/j.annonc.2019.10.026

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries.

Keywords: ESMO guidelines; NSCLC; Pan-Asian; consensus; locally-advanced; unresectable.

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Asia
Carcinoma, Non-Small-Cell Lung* / diagnosis
Carcinoma, Non-Small-Cell Lung* / therapy
China
Humans
India
Japan
Lung Neoplasms* / diagnosis
Lung Neoplasms* / therapy
Malaysia
Medical Oncology
Republic of Korea
Taiwan